Acquisition Announced

Novartis acquisition of Avidity Biosciences

US$11bn enterprise value

Announced 26 Oct 2025 · NYSE: RNA · US$72.00 cash per share

Advisers

Avidity Biosciences

Target

Financial adviser
Legal adviser
Fairness opinion

Novartis

Acquirer

Financial adviser
Target
Avidity Biosciences
Acquirer
Novartis
Target based in
United States
Buyer based in
Switzerland
Equity value
US$12bn
Sector
Biotech
Tags
Biotech, Rare Disease, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.